Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL

• Verfasst von: Schiffer, Charles A. [VerfasserIn]
• Verfasst von: Hehlmann, Rüdiger [VerfasserIn]
• Verfasst von: Larson, Richard A. [VerfasserIn]
• Titel: Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL
• Verf.angabe: C.A. Schiffer, R. Hehlmann and R. Larson
• E-Jahr: 2003
• Jahr: 08 April 2003
• Umfang: 9 S.
• Fussnoten: Gesehen am 12.05.2022
• Titel Quelle: Enthalten in: Leukemia
• Ort Quelle: London : Springer Nature, 1997
• Jahr Quelle: 2003
• Band/Heft Quelle: 17(2003), 4, Seite 691-699
• ISSN Quelle: 1476-5551
• DOI: doi:10.1038/sj.leu.2402879
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Cancer Research
• Sach-SW: general
• Sach-SW: Hematology
• Sach-SW: Intensive / Critical Care Medicine
• Sach-SW: Internal Medicine
• Sach-SW: Medicine/Public Health
• Sach-SW: Oncology
• K10plus-PPN: 1801674310

Abstract

Chronic myeloid leukaemia (CML) is a malignant disease of the bone marrow characterised by the presence of the Philadelphia (Ph) chromosome. About 20% of acute lymphoblastic leukaemia (ALL) patients also show this genetic abnormality. A new drug, imatinib (Glivec®, Novartis Pharma AG, Basel, Switzerland, and formerly STI571) is having a profound effect on the treatment and management of all stages of CML and Philadelphia chromosome positive (Ph+) ALL. New treatment algorithms are being developed. Should imatinib replace or be combined with existing therapies? To address this question, we review the pros and cons of therapy with interferon-α (IFN-α), allogeneic transplantation, autologous transplantation, imatinib, and in the case of Ph+ ALL, chemotherapy and experimental approaches. Conservative and aggressive treatments will be discussed and new molecular methods of monitoring cytogenetic response and their significance will also be reviewed.